Content about Selective serotonin reuptake inhibitors

January 22, 2014

Takeda Pharmaceuticals and Lundbeck announced the availability of Brintellix (vortioxetine), a once-daily oral antidepressant for treatment of major depressive disorder in adults.

DEERFIELD, Ill. — Takeda Pharmaceuticals U.S.A. and Lundbeck on Tuesday announced the availability of Brintellix (vortioxetine) — a once-daily oral antidepressant for treatment of major depressive disorder in adults — in pharmacies across the United States.

“MDD continues to be a challenging condition to manage, and we are proud to make Brintellix available as a new treatment option for people struggling with major depression,” said Douglas Cole, president of Takeda Pharmaceuticals U.S.A.

October 1, 2013

The Food and Drug Administration has approved a new drug developed by Takeda to treat major depressive disorder, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug developed by Takeda to treat major depressive disorder, the agency said.

The FDA announced the approval of Brintellix (vortioxetine) tablets for treating MDD in adults. The drug will be available in the 5-mg, 10-mg, 15-mg and 20-mg strengths.

March 14, 2013

The Food and Drug Administration has approved a drug for obsessive compulsive disorder made by Par Pharmaceutical Cos., the drug maker said Thursday.

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a drug for obsessive compulsive disorder made by Par Pharmaceutical Cos., the drug maker said Thursday.

Par announced the approval and shipment of fluvoxamine maleate extended-release capsules in the 100-mg and 150-mg strengths. The drug is a generic version of Jazz Pharmaceuticals' Luvox CR.

September 13, 2012

The Food and Drug Administration has approved a generic psychiatric drug made by Lupin Pharmaceuticals, Lupin said Thursday.

BALTIMORE — The Food and Drug Administration has approved a generic psychiatric drug made by Lupin Pharmaceuticals, Lupin said Thursday.

The Indian drug maker announced the approval of escitalopram tablets in the 5-mg, 10-mg and 20-mg strengths, used for acute and maintenance treatment of major depressive disorder in adults and adolescents and for acute treatment of general anxiety disorder in adults.

March 22, 2012

Teva Pharmaceutical Industries Ltd. announced on March 14 that it has commenced commercial launch of escitalopram oxalate tablets, the company’s generic version of Forest Laboratories’ depression and generalized anxiety disorder treatment Lexapro tablets.

Teva Pharmaceutical Industries Ltd. announced on March 14 that it has commenced commercial launch of escitalopram oxalate tablets, the company’s generic version of Forest Laboratories’ depression and generalized anxiety disorder treatment Lexapro tablets.

The branded product had annual sales of approximately $2.9 billion in the United States, based on IMS sales data. As the first company to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

March 14, 2012

The Food and Drug Administration has approved the first generic version of an antidepressant made by Forest Labs, the agency said Wednesday.

SILVER SPRINGS, Md. — The Food and Drug Administration has approved the first generic version of an antidepressant made by Forest Labs, the agency said Wednesday.

The FDA announced the approval of a generic version of Lexapro (escitalopram) made by Teva Pharmaceutical Industries in the 5-mg, 10-mg and 20-mg strengths. The drug is used to treat depression and generalized anxiety disorder in adults.

February 29, 2012

Mylan has launched a generic drug for treating depression and anxiety, the company said Wednesday.

PITTSBURGH — Mylan has launched a generic drug for treating depression and anxiety, the company said Wednesday.

Mylan announced the launch of escitalopram tablets in the 5-mg, 10-mg and 20-mg strengths, the first generic version of Forest Labs' Lexapro. The drug is used for treating major depressive disorder and generalized anxiety disorder.

February 28, 2012

GlaxoSmithKline can sell an authorized generic of its antidepressant drug to Toronto-based drug maker Apotex, a U.S. judge ruled.

NEW YORK — GlaxoSmithKline can sell an authorized generic of its antidepressant drug to Toronto-based drug maker Apotex, a U.S. judge ruled.

According to a Bloomberg Businessweek report, U.S. District Court judge Joe Pisano ruled the agreement was valid.

October 21, 2011

More than 1-in-10 Americans ages 12 years and older take antidepressants, and the rate of antidepressant use in the United States among all ages increased 400% between 1988 and 2008, according to a new report by the Centers for Disease Control and Prevention's National Center for Health Statistics.

ATLANTA — More than 1-in-10 Americans ages 12 years and older take antidepressants, and the rate of antidepressant use in the United States among all ages increased 400% between 1988 and 2008, according to a new report by the Centers for Disease Control and Prevention's National Center for Health Statistics.

October 11, 2011

The Food and Drug Administration has approved a new strength for a psychiatric drug made by Edgemont Pharmaceuticals, Edgemont said Tuesday.

AUSTIN, Texas — The Food and Drug Administration has approved a new strength for a psychiatric drug made by Edgemont Pharmaceuticals, Edgemont said Tuesday.

The drug maker announced the approval of a 60 mg dose of fluoxetine tablets, a treatment for major depressive disorder, obsessive compulsive disorder, bulimia nervosa and panic disorder. The drug was originally marketed under the brand name Prozac.

March 28, 2011

The generics division of drug maker Pfizer is recalling supplies of two drugs due to possible mislabeling.

PEAPACK, N.J. — The generics division of drug maker Pfizer is recalling supplies of two drugs due to possible mislabeling.

Greenstone announced Saturday that it would voluntarily recall 100-count bottles of citalopram 10-mg tablets and 90-count bottles of finasteride 5-mg tablets with the lot number FI0510058-A on the label. The company said a third-party manufacturer may have placed incorrect labels on the bottles. No other lots are affected.

Citalopram is used to treat depression, while finasteride is used to treat benign prostatic hyperplasia.

March 1, 2011

Patients who take generic antidepressants will remain as adherent as those who take brand-name drugs to treat the condition, according to a new study.

ST. LOUIS — Patients who take generic antidepressants will remain as adherent as those who take brand-name drugs to treat the condition, according to a new study.

The study, conducted by Express Scripts and published in the Journal of Managed Care Pharmacy, found patients starting generic selective serotonin reuptake inhibitors and generic selective norepinephrine reuptake inhibitors had a discontinuation rate of 44.2%, compared with 46.8% among those on brand-name SSRIs and SNRIs.

February 23, 2011

Drug maker Forest Labs plans to acquire the developer of a recently approved antidepressant.

NEW YORK — Drug maker Forest Labs plans to acquire the developer of a recently approved antidepressant.

Forest announced that it would pay $1.2 billion, or $30 per share, to acquire Clinical Data, saying the acquisition would give it control of the drug Viibryd (vilazodone hydrochloride), a treatment for major depressive disorder in adults that won Food and Drug Administration approval last month. The agreement also includes up to $6 per share in addition for milestones related to Viibryd.

December 17, 2010

Many older Americans prescribed antidepressants may be taking medication that could adversely interact with the antidepressant, a new study found.

ANN ARBOR, Mich. — Many older Americans prescribed antidepressants may be taking medication that could adversely interact with the antidepressant, a new study found.

November 14, 2010

The often wide gap between what consumers will pay out of pocket for a branded...

NEW YORK —The often wide gap between what consumers will pay out of pocket for a branded versus a generic drug is one big factor driving the continually rising demand curve for me-too medicines.

October 26, 2010

British drug maker GlaxoSmithKline will pay nearly $1 billion to the U.S. government to settle...

LONDON British drug maker GlaxoSmithKline will pay nearly $1 billion to the U.S. government to settle allegations that it sold contaminated and ineffective products.

 

The company will plead guilty to criminal charges relating to drugs made at a manufacturing plant in Cidra, Puerto Rico, which it closed in 2009, and pay $750 million. In a whistleblower suit filed by a former employee, it was alleged that the company knowingly sold defective supplies of various drugs, including the baby ointment Bactroban (mupirocin) and the antidepressant Paxil (paroxetine).

October 18, 2010

A U.S. District Court denied a motion for a preliminary injunction filed by Mylan to...

PITTSBURGH A U.S. District Court denied a motion for a preliminary injunction filed by Mylan to prevent Canadian generic drug maker Apotex from making a generic version of an extended-release antidepressant drug, Mylan said Monday.

 

Mylan said the U.S. District Court for the District of New Jersey erred in its decision, and it intends to appeal.

 

 

September 21, 2010

A U.S. District Court has blocked Canadian generic drug maker Apotex from selling generic versions...

PITTSBURGH A U.S. District Court has blocked Canadian generic drug maker Apotex from selling generic versions of an antidepressant drug.

 

Generic drug maker Mylan said Tuesday that it had obtained a temporary restraining order from the U.S. District Court for the District of New Jersey prohibiting Apotex from selling generic versions of the drug Paxil CR (paroxetine hydrochloride), an extended-release formulation of GlaxoSmithKline’s Paxil.

 

 

September 15, 2010

Drug maker Forest Pharmaceuticals will pay more than $300 million to the federal government as...

SILVER SPRING, Md. Drug maker Forest Pharmaceuticals will pay more than $300 million to the federal government as part of a plea agreement over alleged improper drug distribution and obstructing a Food and Drug Administration inspection.

August 25, 2010

Teva Pharmaceutical Industries has launched a generic version of a weekly formulation of a popular...

NORTH WALES, Pa. Teva Pharmaceutical Industries has launched a generic version of a weekly formulation of a popular antidepressant, the generic drug maker said.

 

Teva announced the launch of fluoxetine delayed-release capsules, a generic version of Eli Lilly’s Prozac Weekly.

 

NORTH WALES, Pa. Teva Pharmaceutical Industries has launched a generic version of a weekly formulation of a popular antidepressant, the generic drug maker said.

 

August 10, 2010

The drug market for unipolar depression will get smaller over the next decade due to...

May 31, 2010

A new Consumer Reports health survey found that nearly 80% of respondents seeking treatment for...